FibroBiologics (FBLG) vs Soligenix (SNGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
FibroBiologics is the larger company by market cap ($7.7 million vs $7.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FBLG | SNGX |
|---|---|---|
| Share price | $1.11 | $0.3466 |
| Market cap | $7.72M | $7.54M |
| 1-day change | -2.63% | -1.95% |
| EPS (TTM) | $-5.01 | $-0.79 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.98 | $1.80 |
| 52-week low | $0.62 | $0.28 |
| Distance from 52-week high | -88.88% | -80.74% |
| Analyst consensus | none | none |
| Avg. price target upside | +1026.13% | +298.15% |
| Average volume | 204.44K | 249.87K |
| Shares outstanding | 6.96M | 21.77M |
| Employees | 15 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About FibroBiologics
FBLG stock →FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About Soligenix
SNGX stock →Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
FBLG vs SNGX FAQ
Which is bigger, FibroBiologics or Soligenix?
FibroBiologics (FBLG) is larger, with a market capitalization of $7.72M compared with $7.54M for Soligenix (SNGX).
Are FibroBiologics and Soligenix in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.